Analysis of the short?term clinical efficacy of anlotinib combined with PD?1 inhibitors in treatment of advanced non?small cell lung cancer patients and its effects on serum VEGF and MMP?2 levels

GAO Hang; YIN Jun; LI Yanwu

doi:10.3969/j.issn.1674-3806.2023.07.15

Home>Articles>Analysis of the short?term clinical efficacy of anlotinib combined with PD?1 inhibitors in treatment of advanced non?small cell lung cancer patients and its effects on serum VEGF and MMP?2 levels

DOI: 10.3969/j.issn.1674-3806.2023.07.15

Analysis of the short?term clinical efficacy of anlotinib combined with PD?1 inhibitors in treatment of advanced non?small cell lung cancer patients and its effects on serum VEGF and MMP?2 levels

GAO Hang

YIN Jun

LI Yanwu

Keywords：AnlotinibProgrammed death⁃1(PD⁃1) inhibitorAdvanced non⁃small cell lung cancerVascular endothelial growth factor(VEGF)Matrix metalloproteinase⁃2(MMP⁃2)Clinical efficacy

Publication Date：2023-07-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：5( 716-720 )

Chinese Journal of New Clinical Medicine

ISTIC

ISSN：1674-3806

Year, Vol.(Issue)：2023,16(7)